✦ LIBER ✦

Hereditary hemorrhagic telangiectasia/avastin

✍ Scribed by Terence M. Davidson; Scott E. Olitsky; Julie L. Wei

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 389 KB
Volume: 120
Category: Article
ISSN: 0023-852X
DOI: 10.1002/lary.20757

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

This is the first scientific report of hereditary hemorrhagic telangiectasia (HHT) epistaxis treatment by intranasal spraying of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin). Epistaxis in patients with HHT is a morbid, mortal condition that is difficult and unpleasant to manage. Nasal telangiectasia growth is modulated by VEGF, which is elevated in HHT patients. Bevacizumab is a VEGF inhibitor that diminishes epistaxis when administered intravenously or injected locally, or as reported here when sprayed topically onto the nasal mucosa. Laryngoscope, 2010

📜 SIMILAR VOLUMES

In reference to Hereditary Hemorrhagic T

In reference to Hereditary Hemorrhagic Telangiectasia/Avastin

✍ Gregor Bachmann-Harildstad 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 39 KB

The effect of bevacizumab (Avastin) trea

The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia

✍ Jana Simonds; Frank Miller; Jess Mandel; Terence M. Davidson 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB

## Abstract ## Objectives/Hypothesis: Determine the effectiveness of treating epistaxis in hereditary hemorrhagic telangiectasia (HHT) with potassium titanyl phosphate (KTP) laser cautery combined with submucosal injection of 100 mg of bevacizumab. ## Study Design: Retrospective pilot study. ##

Safety of intranasal Bevacizumab (avasti

Safety of intranasal Bevacizumab (avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

✍ Sonia Chen IV; Tom Karnezis; Terence M. Davidson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## Objectives/Hypothesis: Assess for complications of intranasal Bevacizumab application in patients with hereditary hemorrhagic telangiectasia (HHT)‐associated epistaxis. ## Study Design: Retrospective chart review. ## Methods: In 58 patients presenting with recurrent HHT epistaxi

Efficacy of intranasal bevacizumab (Avas

Efficacy of intranasal bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis

✍ Tom T. Karnezis; Terence M. Davidson 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 78 KB

## Abstract ## Objectives/ Hypothesis: Intranasal Bevacizumab is an effective therapy for epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT). ## Study Design: Retrospective chart review. ## Methods: In 32 successive patients presenting with recurrent HHT epistaxis 25–100 mg

Hereditary Hemorrhagic Telangiectasia

✍ Timo Krings; Augustin Ozanne; Soke M. Chng; Hortensia Alvarez; Georges Rodesch; 📂 Article 📅 2006 🏛 Springer 🌐 German ⚖ 878 KB

Imaging of Hereditary Hemorrhagic Telang

Imaging of Hereditary Hemorrhagic Telangiectasia

✍ Marie-France Carette; Cosmina Nedelcu; Marc Tassart; Jean-Didier Grange; Marie W 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 868 KB